Recorded at the ESMINT TV Studio 2026, this WallabyPhenox Industry Slot brings together Prof. Jens Fiehler, Dr Paul Bhogal, Prof. Aymeric Rouchaud and Prof. Adnan Siddiqui to explore the company’s heritage of clinically led innovation and its continued development as a global neurovascular technology business.

Prof. Siddiqui reflects on WallabyPhenox’s broad portfolio of innovations across intrasaccular treatment, stent-assisted techniques, intracranial atherosclerotic disease, flow diversion and mechanical thrombectomy. He highlights the company’s commitment to robust clinical evidence, including its decision to evaluate new technologies through randomised controlled trials and direct comparison with established standards of care.

The discussion examines the evolving role of surface modification and antiplatelet strategies in flow diversion. Prof. Rouchaud shares insights into preclinical research using multimodal assessment, including angiography, histology, optical coherence tomography and multiphoton imaging, while considering how collaboration between academic centres and research and development teams can strengthen device evaluation and guide future innovation.

Dr Bhogal reflects on his experience working with the Phenox team in Stuttgart and discusses how close cooperation between clinicians and engineers has shaped devices designed to address specific procedural challenges. The panel also explores emerging approaches to middle meningeal artery embolisation for chronic subdural haematoma, including the potential roles of coils, liquid embolic agents, drug delivery and the need for further randomised evidence.

Moderated by Prof. Fiehler, the session concludes with an expert discussion on clinical observation, iterative engineering, international collaboration and the importance of generating meaningful evidence alongside technological development.

The session provides a wide-ranging perspective on the clinical, scientific and engineering foundations of WallabyPhenox, highlighting how a continued focus on innovation, courage and disruption may support the next stage of its global development.